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Abstract
Aims/hypothesis Autoantibodies against pancreatic islets and
infections by enteroviruses are associatedwith type 1 diabetes,
but the specificity of immune responses within the type 1
diabetic pancreas is poorly characterised. We investigated
whether pancreatic lymph nodes could provide a source of
antigen-specific B cells for analysis of immune responses
within the (pre)diabetic pancreas.
Methods Human IgG antibodies were cloned from single B
lymphocytes sorted from pancreatic lymph node cells of three
organ donors positive for islet autoantibodies, and from the
peripheral blood of a patient with type 1 diabetes. Antibodies
to insulinoma-associated antigen 2 (IA-2), GAD65, zinc trans-
porter 8 (ZnT8) and Coxsackie B virus proteins were assayed
by immunoprecipitation and by immunofluorescence on pan-
creatic sections.
Results Human IgG antibodies (863) were successfully
cloned and produced from 4,092 single B cells from lymph
nodes and peripheral blood. Reactivity to the protein tyrosine
phosphatase domain of the IA-2 autoantigen was detected in
two cloned antibodies: one derived from a pancreatic lymph
node and one from peripheral blood. Epitopes for these two
antibodies were similar to each other and to those for circulat-
ing antibodies in type 1 diabetes. The remaining 861 antibod-
ies were negative for reactivity to IA-2, GAD65 or ZnT8 by
both assays tested. Reactivity to a Coxsackie viral protein 2
was detected in one antibody derived from a peripheral blood
B cell, but not from lymph nodes.
Conclusions/interpretation We show evidence for the infre-
quent presence of autoantigen-specific IgG+ B lymphocytes
in the pancreatic-draining lymph nodes of islet autoantibody-
positive individuals.
Keywords Autoantibodies . Coxsackie virus . IgG
expression . Single-cell PCR . Type 1 diabetesmellitus
Abbreviations
BCR B cell receptor
CDR3 Complementarity determining region 3
FLuc Firefly luciferase
hAb Human antibodies
HEK Human embryonic kidney
HEV Human enterovirus
IA-2 Insulinoma-associated antigen 2
JM Juxtamembrane
LIPS Luciferase immunoprecipitation system
PBMC Peripheral blood mononuclear cells
PTP Protein tyrosine phosphatase
RLuc Renilla luciferase
VP Viral protein
ZnT8 Zinc transporter 8
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Introduction
Type 1 diabetes is associated with autoimmunity to islet cell
proteins and with enteroviral infections in the inflamed pan-
creatic islet [1, 2]. Little, however, is known about the speci-
ficity or site of immune responses during pancreatic inflam-
mation in type 1 diabetes. Immune responses are expected to
occur within the diabetic pancreas [3], but molecular mimicry
or immunisation at sites distant to the islets has also been
suggested [4]. Few studies have examined lymphoid cells
within the pancreas for evidence of autoreactive T and B cells.
Insulin-reactive CD4+ T cells have been demonstrated in pan-
creatic lymph nodes of a patient with long-standing type 1
diabetes [5], proinsulin-reactive CD4+ T cells have been
cloned from pancreatic islets of a patient [6], and islet-
specific glucose-6-phosphatase catalytic subunit-related pro-
tein-specific CD8+ T cells have been observed within islets in
pancreas sections of a patient with type 1 diabetes [7]. B lym-
phocytes are often found within islets [8], but the specificity of
those in and around the pancreas is unknown. We had the
opportunity to study pancreatic lymph nodes of organ donors
who were islet autoantibody-positive and investigated wheth-
er the B cells within these were specific for antigens implicat-
ed in the pathogenesis of type 1 diabetes.
Methods
Donors and lymphocyte source
Lymph nodes were obtained from pancreases of organ donors
in the Nordic Network for Islet Transplantation (Table 1). Sera
from organ donors were tested for autoantibodies to GAD65
and to insulinoma-associated antigen 2 (IA-2) and, if positive,
pancreases were processed and lymphoid tissue retrieved.
Multiple pancreatic lymph nodes were isolated from each of
three islet autoantibody-positive organ donors (PLN1, PLN2
and PLN3). Lymph node cells were dissociated, washed and
frozen in serum/DMSO. Peripheral blood mononuclear cells
(PBMC) were obtained from a patient (PBMC1) with type 1
diabetes at onset of disease. Collection of material was ap-
proved by local ethics review boards (Regional Ethics Com-
mittee in Uppsala: Dnr 2009/043 and Dnr 2009/371 [2012 12
16]; Bayerische Landesärztekammer in Munich). CD19+ B
lymphocytes were isolated by magnetic bead isolation
(Miltenyi Biotec, Bergisch Gladbach, Germany), stained with
anti-CD19–phycoerythrin and anti-IgG–FITC (BD Biosci-
ences, San Diego, CA, USA), and single live CD19+IgG+
lymphocytes sorted on a Becton Dickinson FACSAria II flow
cytometer (Becton, Dickinson, Franklin Lakes, NJ, USA) into
individual wells of PCR plates containing 10 μl TRIS+1 μl
RNasin (Promega, Madison, WI, USA).
IgG production
Single-cell RT and a first PCR with constant region 3′
primers and a mix of 4-, 3- and 7-signal peptide se-
quence primers covering all subgroups of heavy chain,
kappa and lambda light chains, respectively (electronic
supplementary material [ESM] Table 1), was performed
directly on cells. A second nested PCR was used to
amplify the entire variable and partial constant regions
of the chains, and to N-terminally fuse these to the
METDTLLLVLLLWVPGSTGD signal peptide. This
was assembled into the remaining constant region, with
cytomegalovirus promoter and polyadenylation signal,
and transfected into human embryonic kidney (HEK)
293 T cells using PolyFect Reagent (Qiagen, Hilden,
Germany). After 48 h, IgG concentration in supernatant
fractions was measured by ELISA (ESM Fig. 1 and
ESM Methods).
Antibody screening
Antigens of interest were N-terminally fused to Firefly
luciferase (FLuc), Renilla luciferase (RLuc) or NanoLuc
luciferase (Promega) and cloned into the pTNT vector
(Promega). The following constructs were used to cover
all known autoantibody epitopes of the antigens
pTNTFLuc-IA-2 (amino acids 605–979), pTNTRLuc-
GAD65 (96–585), pTNTFLuc-IA-2/zinc transporter 8
[ZnT8] WR (IA-2: 605–979; ZnT8W: 268–369,
R325W; ZnT8R: 268–369), pTNTFLucZnT8W (268–
369, R325W) and pTNTRLucZnT8R (268–369), as well
as human enterovirus (HEV) fusion constructs as de-
scribed (ESM Table 2). Fusion proteins were produced
using SP6- or T7-based TNT-coupled rabbit reticulocyte
system (Promega). For screening of antibody specificity,
10 μl clone supernatant fraction was incubated with
25 μl luciferase fusion protein (107 relative light units
[RLU]/well for FLuc or RLuc fusion proteins, 5×106
RLU/well for NanoLuc and for HEV fusion proteins)
in TRIS-buffered saline/Tween 20 and immune-
precipitation assays performed (ESM Methods).
IA-2 epitope mapping of the human antibodies (hAb)
was performed using constructs containing cytoplasmic
IA-2 (amino acid 605–979), juxtamembrane (JM; 605–
693), protein tyrosine phosphatase (PTP; 643–979) or
central IA-2 PTP (643–937) regions, and alanine-
substituted mutants of these, using radiobinding assays
as previously described [9]. Inhibition by >50% was
taken as evidence that amino acid substitution affected
binding.
Immunofluorescence (ESM Methods) was performed on
ready-to-use frozen monkey pancreas sections (Bio-Diagnos-
tics, Upton-upon-Severn, UK).
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Results
Generation of hAb from single CD19+IgG+ B lymphocytes
A total of 2,832 CD19+IgG+ B lymphocytes were isolated
from pancreatic lymph nodes and 1,260 from PBMC
(Table 1). IgG heavy and light chain variable region pairs were
amplified from 1,526 of 4,092 single cells (37% PCR efficien-
cy, comparable to data given in [10]), and, after heavy and
light chain assembly and transfection of HEK 293 Tcells, IgG
was detected in 863 (21% of isolated B cells) of the superna-
tant fractions.
Complementarity determining region 3 (CDR3) of the
heavy and light chain PCR products from PLN1 and from
PBMC1 were sequenced, and 571 heavy chain, 280 kappa
light chain and 125 lambda light chain readable sequences
were obtained (www.crt-dresden.de/research/crtd-core-
groups/bonifacio.html, accessed 1 June 2015; ESM Fig. 2).
The same heavy or light chain sequence was not found in
more than one cell from lymph nodes, but examples were
seen in cells derived from peripheral blood (not shown).
Identification of islet autoantigen-specific hAb
The hAb were tested for their ability to bind the major
autoantigens GAD65 and IA-2 and the two isoforms of
ZnT8 (R and W). Four hAb showed increased binding to the
IA-2/ZnT8R/W fusion protein (Fig. 1a), and two of these
(PBMC1_A5 and PLN1_C11) were subsequently shown to
strongly bind IA-2-luciferase, but not ZnT8R- or ZnT8W-
luciferase (Fig. 1b). No hAb bound GAD65-luciferase.
Both PBMC1_A5 and PLN1_C11 bound the PTP- and the
central region constructs, indicating that their epitopes are includ-
ed within amino acids 643–937 of IA-2 (Fig. 1c). Reactivity was
further characterised using single amino acid mutants within the
region 826–862, previously shown to encompass a major IA-2
epitope [9] (Fig. 1d). The binding profiles for the two hAb were
almost identical and similar to that of existing hAb 96/3, despite
different CDR3 amino acid sequences (PBMC1_A5: heavy
c h a i n CAKDSHVVAATPFDYW, l i g h t c h a i n
CQTWATGL #V F ; P LN 1 _ C 11 : h e a v y c h a i n
CAKEKWNFYDGSGYSSGYDYW, l i gh t cha i n
CQQAKDFPITF; 96/3: heavy chain CARVLKGVATASFDFW,
light chain CQVWDTRSDLVVF; ESM Table 3). Binding was
markedly reduced by the mutations L831A, V834A, E836A,
L839A, K857A, N858A, V859A or Q862A.
All hAb were also tested for reactivity to pancreatic islets,
using immunofluorescence on sections of monkey pancreas. A
strong islet-specific signal could be detected with the IA-2-
binding PBMC1_A5 and with the control IA-2-specific hAb
96/3, but not with the IA-2-binding PLN1_C11 (Fig. 1e). None
of the remaining hAb showed reactivity to monkey pancreas
sections.
Reactivity of the hAb against HEV antigen
Type 1 diabetes is associated with Coxsackie B virus infection,
with evidence of enteroviral proteins present in the inflamed islet
[2]. We therefore examined whether any of the 863 hAb bound
Table 1 Cells and monoclonal antibodies produced and analysed, with description of samples used and characteristics of type 1 diabetic patients
B lymphocyte source GAD65/IA-2
antibodies, U/ml
HbA1c, %
(mmol/mol)
HLA IgG+CD19+
cells isolated, n
Successful heavy and
light chain products,
n (%)
Productive
hAb, n (%)
PLN1
Female islet donor
Age at sampling: 37 years
Pancreatic lymph nodes
10/30 5.3 (34.4) A3/31, B35/39, DR1/9 576 335 (58) 215 (37)
PLN2
Male islet donor
Age at sampling: 63 years
Pancreatic lymph nodes
13/64 5.2 (33.3) A1/30, B18/60, DR1/3 768 196 (26) 105 (14)
PLN3
Male islet donor
Age at sampling: 59 years
Pancreatic lymph nodes
10,600/negative 5.8 (39.9) A3/10, B7/12, DR3/15 1,488 459 (31) 261 (17.5)
PBMC1
Male donor with new-onset
type 1 diabetes
Age at sampling: 30.5 years
(0.2 years after onset)
PBMC
1,000/1,000 NA HLA DRB1*03/*04
DQB1*02/*0302
1,260 536 (43) 282 (22)
Total 4,092 1,526 (37) 863 (21)
NA, not available
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constructs representing the majority of the viral protein (VP)
antigens found in Coxsackie B virus 1–6 using luciferase immu-
noprecipitation system (LIPS) assays (ESM Fig. 3). Only one
hAb, PBMC1_A6, boundCoxsackieB virus protein, specifically
the luciferase-CV-B1 VP2. Serum obtained from the same pa-
tient was positive against the same construct (not shown).
Discussion
We sought evidence for B cells against autoantigen and
Coxsackie B virus in the lymph nodes of islet autoantibody-
positive organ donors. One pancreatic lymph node-derived B
cell was specific for IA-2 and therefore provided evidence for
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Fig. 1 (a) Immunoprecipitation assays for reactivity against IA-2, ZnT8
and GAD65. Dual-luciferase LIPS assays were performed on 863 hAb
with FLuc fused to the IA-2 and ZnT8R/W antigens and RLuc fused to
the GAD65 antigen. Binding was expressed as an index against the neg-
ative control. (b) Four hAb bound to the IA-2/ZnT8R/W fusion protein
(PBMC1_A5, PLN1_C11, PBMC1_E3 and PLN3_F6) with an index
>20, and were tested using single constructs containing IA-2, ZnT8R
and ZnT8W. PBMC1_A5 and PLN1_C11 showed reactivity only for
IA-2. PBMC1_E3 and PLN3_F6 did not bind any of these fusion proteins
(index <20). None of the hAb were considered positive against GAD65
(a). Black bars, IA-2/ZnT8R/W; grey bars, IA-2; white bars, ZnT8R;
striped bars, ZnT8W. (c) Mapping of the binding region of PBMC1_A5
(white bars) and PLN1_C11 (black bars). Using epitope mapping with
IA-2 deletion mutants (indicated on the x-axis), both hAb were shown to
react with the IA-2 region 643–979 (PTP and central regions) in
radiobinding assays. Binding is expressed as counts per minute (cpm).
(d) Fine-mapping of the binding region of PBMC1_A5 and PLN1_C11.
Single mutations in the central PTP region (aa 826 to aa 862, indicated in
the x-axis) revealed that PBMC1_A5 and PLN1_C11 had comparable
IA-2 amino acid requirements for binding. •Antibody binding <50%with
respect to the wild-type protein. (e) Staining of monkey pancreatic sec-
tions with hAb (upper panels, magenta); staining with PBMC1_A5 and
PLN1_C11, with anti-IA-2 (96/3) and GAD65 hAb as positive controls
and a GAD-, IA-2- and ZnT8-negative antibody (PLN1_D10) as negative
control, and co-staining for insulin (lower panels, cyan). aa, amino acid;
mAb, monoclonal antibody
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B cell priming against autoantigen, but we found no evidence
of B cells reactive to Coxsackie B virus in the pancreatic
lymph nodes.
We had expected pancreatic lymph node B cells to be
an enriched source of islet autoantibodies. However, B
cells directed against pancreatic islet antigens were rare
in the lymph nodes we studied. A previous study exam-
ining plasma cells in the cerebrospinal fluid of patients
with multiple sclerosis also showed low frequencies of
autoantigen-specific antibody-producing B cells in the
vicinity of the lesions [11]. Unfortunately we could
not investigate binding to one of the major islet
autoantigens, insulin, due to high interference in the
assays. We cannot exclude that the low frequency of
islet antigen reactive B cells detected in our study was
the consequence of sequence artefacts introduced during
the cloning that affected the CDR3-binding region of
the B cell receptors (BCRs). Nevertheless, the study
produced two antibodies against IA-2, one from a
lymph node and one from peripheral blood, both to
the PTP region, with binding profiles similar to each
other and to other type 1 diabetes-derived autoanti-
bodies [9]. This epitope, therefore, is a common target
of autoreactive B cells in type 1 diabetes. Subtle differ-
ences in the fine specificity of the two IA-2 autoanti-
bodies were shown on the basis of reactivity with mu-
tated IA-2 constructs and heterogeneous reactivity with
islets on monkey pancreas. Absent reactivity on monkey
pancreas for one antibody may be due to an amino acid
difference at position 862 between human and macaque
IA-2.
Because of reports of HEV infection in the type 1 diabetic
pancreas [2], we looked for evidence of pancreatic lymph
node B cells directed to Coxsackie proteins. Although we
were able to identify one Coxsackie B virus-specific BCR
from peripheral blood B cells, we did not see binding from
the lymph node-derived BCRs. This may either indicate that
the patients had little or no exposure to Coxsackie B virus in
the pancreas or that our methods were inadequate to faithfully
produce hAb.
In summary, we provide evidence that there are IgG+ B
lymphocytes primed against islet autoantigen at low frequen-
cy in lymph nodes that drain the pancreas of islet
autoantibody-positive individuals.
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